Our people

Our experienced team of industry experts

 

Our leadership team

Sentinel Oncology is a drug discovery company passionate about the development of novel therapeutics to treat cancer patients for whom there is currently an unmet medical need. The company’s mission is to discover and develop a pipeline of novel drugs that can treat primary and metastatic brain tumours. The Sentinel Oncology management team has extensive experience in drug research and development and is committed to innovations that improve patients’ lives.

  • Robert G Boyle

    Robert G Boyle

    Founder & CEO

  • Stuart Travers

    Stuart Travers

    Founder & COO

  • David Walker

    David Walker

    Director of Chemistry

  • Dr Meriel Major

    Dr Meriel Major

    Associate Director, Chemistry

  • Dr Grahame Mckenzie

    Dr Grahame Mckenzie

    Director of Biology

 
 

Our Board & Advisors

Sentinel Oncology is supported by an experienced team of advisors, bring invaluable expertise in clinical trials and drug development.

  • Professor Ashok Venkitaraman

    Professor Ashok Venkitaraman

    Chair of SAB & Board of Directors

  • Professor Anthony Chalmers

    Professor Anthony Chalmers

    Clinical and Brain Cancer Scientific Advisor

  • Professor Duncan Jodrell

    Professor Duncan Jodrell

    Clinical Advisor

  • Andy Baxter

    Andy Baxter

    Drug Development Advisor

  • Dr John Dixon

    Dr John Dixon

    Drug Discovery Advisor & Board of Directors

  • Roy Eady

    Roy Eady

    Regulatory & Scientific Advisor

  • Gavin Simpson

    Gavin Simpson

    Board of Directors

  • Dan Cowell

    Dan Cowell

    Board of Directors

 
 
 

Stay up to date with the latest news and events from Sentinel Oncology